ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Your view on ACAD
Overview
What the company does, where it operates, and who runs it.
About ACADIA Pharmaceuticals Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Catherine E. Owen Adams
- Headquarters
- 12830 El Camino Real, San Diego, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Catherine E. Owen Adams
- Headquarters
- 12830 El Camino Real, San Diego, CA, US
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's.
ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for ACADIA Pharmaceuticals Inc. from FRC's valuation model, read against the market price. ACAD last traded at $18.67, 8.9× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for ACADIA Pharmaceuticals Inc.. Starting points for ACADIA Pharmaceuticals Inc.: P/E 8.9, EPS $2.10, beta 0.89 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for ACADIA Pharmaceuticals Inc.. ACADIA Pharmaceuticals Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for ACADIA Pharmaceuticals Inc.. Trailing twelve-month EPS for ACADIA Pharmaceuticals Inc. stands at $2.10. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$31.50
average of 15 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy12
- Hold4
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.27 | $0.24 | $0.76 | $1.05 |
| Low estimate | $0.17 | $0.11 | $0.56 | $0.48 |
| High estimate | $0.50 | $0.41 | $1.04 | $1.81 |
| No. of analysts | 11 | 3 | 12 | 13 |
| Year-ago EPS | $1.601 | $0.021 | $2.291 | — |
| Growth | — | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $362.59M | $348.42M | $1.28B | $1.44B |
| Low estimate | $355.50M | $331.97M | $1.26B | $1.42B |
| High estimate | $371.66M | $366.56M | $1.29B | $1.50B |
| No. of analysts | 12 | 3 | 14 | 14 |
| Year-ago revenue | $283.99M | $268.06M | $1.07B | — |
| Growth | +27.7% | +30.0% | +19.5% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 17, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for ACADIA Pharmaceuticals Inc.. ACADIA Pharmaceuticals Inc. has reported as a listed company since 2004. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ANROAlto Neuroscience, Inc.Biotechnology$1.1B
- AVXLAnavex Life Sciences Corp.Biotechnology$76M
- AXSMAxsome Therapeutics, Inc.Biotechnology$7.2B
- CTNMContineum Therapeutics, Inc. Class A Common StockBiotechnology$342M
- LBRXLB Pharmaceuticals Inc Common StockBiotechnology$1.4B
- MPLTMapLight Therapeutics, Inc.Biotechnology$294M
- NMRANeumora Therapeutics, Inc. Common StockBiotechnology$69M
- PRAXPraxis Precision Medicines, Inc.Biotechnology$8.7B
More Biotechnology companies
- TLX.AXTelix Pharmaceuticals LimitedASX
- TNGNQTengion, Inc.OTC$4,025
- TNGXTango Therapeutics, Inc.NASDAQ$4.1B
- TNXPTonix Pharmaceuticals Holding Corp.NASDAQ$56M
- TNYATenaya Therapeutics, Inc.NASDAQ$76M
- TOVXTheriva Biologics, Inc.AMEX$6M
- TPSTTempest Therapeutics, Inc.NASDAQ$7M
- TRAWTraws Pharma, Inc.NASDAQ$4M
- TRAXFirst Tracks Biotherapeutics IncNASDAQ$2.0B
- TRDAEntrada Therapeutics, Inc.NASDAQ$196M
- TRP.AXTissue Repair LtdASX
- TRSBF3SBio Inc.OTC$6.2B
ETFs holding ACADIA Pharmaceuticals Inc.
% of the fund
- XUU.TOiShares Core S&P U.S. Total Market Index ETF$4.6B in assets
- IJRiShares Core SP Small-Cap ETF$103.8B in assets0.13%
- IWMiShares Russell 2000 ETF$76.6B in assets0.08%
- XSU.TOiShares U.S. Small Cap Index ETF (CAD-Hedged)$627M in assets0.08%
- SBIOALPS Medical Breakthroughs ETF$187M in assets2.12%
- PBEInvesco Biotechnology & Genome ETF$438M in assets1.69%
- PSCHInvesco S&P SmallCap Health Care ETF$188M in assets1.30%
- ASCEAllspring SMID Core ETF$418M in assets1.26%
Largest holders first, then the funds most concentrated in ACAD.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold ACADIA Pharmaceuticals Inc., and how their positions are changing. At a $3.23B market value, institutional positions materially move ACADIA Pharmaceuticals Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by ACADIA Pharmaceuticals Inc. executives and directors. Shares of ACADIA Pharmaceuticals Inc. have traded between $13.40 and $26.65 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming ACADIA Pharmaceuticals Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for ACADIA Pharmaceuticals Inc.. Coverage tracks ACADIA Pharmaceuticals Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of ACADIA Pharmaceuticals Inc.